At the Advancements in Oncology event, hosted by The Oncology Brothers, Margaret Gatti-Mays, MD, MPH, provided excellent insights into breast cancer treatment innovations. Here, Nera Lopetegui-Lia, MD, of the Taussig Cancer Institute, discusses Dr. Gatti-Mays’ panel, particularly how data from the DESTINY-Breast06 study impact clinical oncology practice.
HER2-Low Metastatic
Advertisement
Enhertu approved in the EU for HR+, HER2-low, -ultralow metastatic breast cancer, showing PFS benefit over chemotherapy.
Cytology provides new insights into HER2-low metastatic breast cancer, revealing proliferative features and survival trends.
A new study validates a HER2-low–focused scoring system to improve diagnostic accuracy in metastatic breast cancer.
Study finds HER2-low vs HER2-zero breast cancer similar overall, but HER2-low shows better RFS if node-positive.
The FDA approved trastuzumab deruxtecan for HR-positive/HER2-low metastatic breast cancer based on DESTINY-Breast06 results.
The FDA granted Fast Track status to emiltatug ledadotin for advanced breast cancer following phase 1 results targeting B7-H4
Dr. Margaret Gatti-Mays delves into the topic of HER2 tumor expression in breast cancer.
Dr. Margaret Gatti-Mays talks with The Oncology Brothers about the right treatments for endocrine-resistant breast cancer.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.